Aotea

Aotea is a New Zealand-based biotechnology company focused on developing a new class of precision medicines through its proprietary single-cell multi-omics platform. Spun out from the University of Auckland, the company leverages high-throughput analysis of tissues to identify molecular drivers of disease at an unprecedented resolution. By integrating genomic, transcriptomic, and proteomic data at the single-cell level, Aotea aims to accelerate the discovery of novel therapeutic targets and the development of personalized treatments. The company is currently in the pre-clinical stage, focusing on building its pipeline and validating its technology in complex disease areas such as oncology and immunology.